Critic’s Notebook: ‘This Way Up’ Is More Than a Spiritual Cousin to ‘Fleabag’ – Hollywood Reporter

As the Emmys and seemingly everyone watching in the audience and at home poured out love for Phoebe Waller-Bridge and her Fleabag, the little show that could but almost didn't (three years ago in this same month a number of rave reviews still had a hard time convincing people to watch), I thought about a different show:This Way Up. It's a series bought by Hulu from its British originators and, well, more on that shortly.

But I also thought how different the massive love for Fleabag this week was from the situation the show was in three years ago, which is helpful when considering an overlooked show like This Way Up, which some are already calling a cousin of sorts to Fleabag.

For starters, five weeks before Fleabag's first seasonpremiered on Amazon as a co-production I wrote a column about how Amazon was struggling, as a new content provider, in differentiating its originals from shows it had streaming rights to, having bought them from others. In short: Amazon shows weren't getting much special love; they were tossed in with the rest of the offerings, like products. It was hard to get noticed that way since people were very new to the idea that Amazon made its own TV series in addition to selling toilet paper and watches, etc.

There wasn't much hype for Fleabag, or advertising. There were 19 reviews for it (including mine) before it aired a paltry amount, but the reviews were glowing (it had a score of 88 on Metacritic, which equates to "universal acclaim"). Still, what followed was months of critics saying, "You should watch this show on Amazon called Fleabag. It's brilliant!" And people would say, "Amazon makes TV shows? And what's a Fleabag? Is sounds gross?"

So, yeah, three years later and four Emmy wins in big categories series, lead actress, writing, directing and the only thing that's changed for other small, dying-to-be-discovered gems is thatit's exponentially harder. Peak TV very clearly hasn't peaked.

But here's the thing This Way Up really is brilliant. Irish actress and comic Aisling Bea (pronounced Ash-ling) created, wrote and stars as a troubled Irish Londoner, recovering from a mental breakdown of unknown origin and gingerly putting her life back in order, but slipping by degrees every day.

When This Way Up came out on Aug. 21, only a measly four outlets reviewed it four! THR's own Dan Fienberg reviewed it favorably, but I happen to like it a lot more than he does (even when critics agree they tend to disagree on the little things). Three of the four reviews mentioned Fleabag (and Catastrophe, another British co-pro from Amazon that starred Sharon Horgan, who is also excellent in This Way Up, which comes from her production company). The gist from those reviews is that This Way Up is really good but flawed and, hey, if you miss Fleabag, this will fill that void, but come up short in the process.

Well, sure, which shows wouldn't? Fleabag is a real rarity, particularly the first season. It's interesting that the four reviews of This Way Up I know three of the critics and like them very much, I will note in case you're getting the wrong vibe here mention that it's not particularly plot-driven and that it tends to ramble a bit.

To which I would add: So does Fleabag season 2 (that's a show I adore and will fight over to prove it but, come on all the resolution comes from the secondary characters and there's a lot of rambling about for our troubled heroine). Other shows that have indistinct plots: Atlanta, Master of None andabout 29 others.

What I saw in This Way Upare all the excellent parts that my three peers also saw, plus a perfectly fine structure, interactions that effectively defined the state of Aisling's character, Aine (pronounced Anya), and an ending that set up a second season I'm extremely eager to know will be coming.

In This Way Up, we meet Aine as she's getting out of a treatment facility (or "spa") after suffering a breakdown. Aine's sister Shona (Horgan) picks Aine up and takes her home, and we flash four months ahead to when Aine looks, on the surface, like she's functioning well enough, just adrift when she's not filling the air with non-stop joking and whipsaw banter. Aisling infuses Aine with that manic sense of "If I just smile and joke around everything will be fine or at least everyone will think I'm fine."

But Shona knows better she worries about Aine walking alone at night, tracking her movements by phone. Her obsessing is our hint that it was more than a breakdown. I thought This Way Upwas excellent at illustrating that the "normal" things going to work, interacting with strangers, cohabitating with a roommate were the moments in Aine's day where she was most vulnerable, where her joys were fleeting, her connections superficial and her separation from family a little too much to bear. For me, the season was about a person trying to cope with life and getting it about 60 percent right on her best days.

The introduction of people beyond Shona her boyfriend (played by Aasif Mandvi), his family, Aine's roommate's family, a humorless employer (Tobias Menzies) who slowly starts falling for her, etc. was less random than it appeared; these were small encounters that brought glimpses of potential light to Aine or further delineated her woes.

What I also saw was something precise and outstanding Aisling herself. It's that feeling I got when Waller-Bridge was at the Television Critics Association summer press tour in August of 2016 andyou just knew. You could see it on the screen and you could see it in person. Aisling has the same kind of tour-de-force sense of humor and her writing in This Way Up is utterly fantastic. She injects her own character with a manic self-deprecation used to keep others at bay just as Waller-Bridge does as Fleabag.

But Fleabag and Aine are suffering from different things it's more well-defined for Fleabag in the first season, without a doubt, but I'd argue the same relative underlying unhappiness she's living through in the second season is just as amorphous as what Aine is going through trying to be happy for a day.

An argument could be made that Fleabag only really and truly cares about Boo in the first season and that vulnerable, unprotected nerve shines through only when she stops using humor and scathing asides as a defense mechanism, just as Aine cares most deeply for others who are suffering and keeps her guard up with family (but only half-up with Shona, whom Aine relies on for emotional support). Both Fleabag and Aine are complex women feeling deep hurt and discontent, the latter often an unexplained or ill-defined emotion which rings so true. Often with depression there's no one reason or easy explanation for why a person is spiraling. And that relentlessly nagging sense of unhappiness is hard to shake precisely because the root of it is indeterminate.

Over the course of six episodes of a mere 23 minutes each, Aisling's writing is a real revelation and her comedic sensibility spot-on. I was surprised at how often I would rewind scenes, marvel at the nuances in the writing scathing humor, bubbling sadness or delight in Aisling's fearless, all-in performance. This series, I thought, is vastly under-appreciated, in addition to having been completely lost in the Peak TV crush (a sentiment that was familiar from three years ago with Fleabag).

I hope more people discover how excellent This Way Up truly is and celebrate its own identity not just flatter it briefly before calling it a cousin to something else.

See the original post:

Critic's Notebook: 'This Way Up' Is More Than a Spiritual Cousin to 'Fleabag' - Hollywood Reporter

Knead & Seed is a haven for spiritual, emotional wellness in Sag Harbor – Northforker

There was a time when Juli Everett was hesitant to call herself a witch, or use the word in relation to her work.

Lately, she has shed that inhibition.

The 32-year-old licensed massage therapist was always called to help others through her lifelong interest in herbology, astrology and other techniques that foster spiritual and emotional wellness. She recalled being a middle school student in Sag Harbor and, after school, walking to Metaphysical Books and Tools, the now defunct Main Street store, to satisfy that innate curiosity at a time when alternative approaches to medicine, healing and self-care were not the trendy cultural fascination is today.

Throughout the years, she has come to reclaim the definition of what it means to be witch.

I believe the definition of a witch is a Woman In Total Control of Herself, she said, before adding, with emphasis, Period.

Personally, my belief is that every woman who walks the earth is a witch. The things that youre the absolute best at, and the things you can create, thats what youre a witch of.

Everett founded Knead and Seed two years ago, and it grew faster, and in different ways than she anticipated, becoming so much more than a massage business. The shop is located in a two-story house on a picturesque piece of property in a secluded and wooded area off Merchants Path, on the border of Sag Harbor and East Hampton.

The space where Everett operates her multi-faceted business is an extension of her personality. A large shelf covers one wall, stacked with books on astrology, massage and other forms she practices. The mantle over a large fireplace features, among other things, photos of both her great-grandmother and aunt, who she cites as big influences in her life. A chalkboard in the small working kitchen has a new message everyday; a deck of oracle cards are fanned out, face down, on a nearby counter.

Everett uses many methods to work with her clients, but usually starts by asking them to pull an oracle card. The simple action is usually enough to get the tears flowing or bring out emotions. Then she takes a look at their chart. Even people who start off as skeptics usually come back for more, she says. Its human nature.

People want to be told about themselves, she said. Thats why were here. We have to help ourselves so that whatever we decide to push out into the universe is successful. Otherwise its BS.

Though she never intended to portray herself as a jack of all trades, she sees a synergy in everything provided at the shop. Among the most popular offerings are the full moon and new moon goddess circle gatherings, where women are invited to come and share what theyve been experiencing and carrying with them in their lives in a judgment-free zone. In less than two years, more than 130 different women have attended the circles, which initially began as a one-time gathering of a few of her closest friends in the first week she was open.

Juli makes you feel accepted, and encourages you to show your truth in a safe environment surrounded by women who are supportive, said client Melissa Lynch. Its very hard to put into words. You just have to try it to understand it. Its something everyone should experience at least once.

She has magic hands, Lynch added. When you walk into Knead and Seed, you immediately feel welcomed.

Creating that feeling of acceptance is exactly what Everett intended. And though Knead and Seeds caters to all, there is no denying its devoted female clientele. Helping women harness their power is at the core of what Everett does, and she hopes to expand that mission with Knead and Seed as time goes by.

I wanted to start a place thats a safe space for women to land and feel validated, she said. I think they come with a sense of wanting to be spiritually connected to themselves with a group of women where everyone can feel validated.

She plans to expand her teaching abilities in the future, and wants to host more retreats, which is a service shes offered more recently. For now, she says she is simply grateful for the people who have walked through her doors, and is proud not only of what she has done for them, but what they have done for themselves.

Im just so thankful to all of the women that have stepped in and have been such a support to this place, she said. But mostly, that they keep showing up for themselves. Im just really thankful that people are becoming more open.

Knead and Seed is located at 146 Merchants Path, Sag Harbor

See the original post here:

Knead & Seed is a haven for spiritual, emotional wellness in Sag Harbor - Northforker

This Darshan and one-day retreat in Eagle will bring spiritual awareness to all who attend – Vail Daily News

Experience a one-day Darshan retreat with spiritual guide Louix Dor Dempriey this weekend in Eagle. All are welcome to attend Darshan with Louix on Friday, Sept. 27 at 7:30 p.m. (by donation). The next day, Dempriey is hosting a one-day retreat from 10 a.m. 6 p.m. Both events will be held at Brush Creek Pavilion Studio.

Darshan is a gift from a spiritual master that can clear away karmic blocks and open chakran. The experience has been known to bring healings, clear the mind and induce states of bliss as well as bring peace and balance. Some have even had epiphanies.

Darshan with Dempriey provides the opportunity for people of all ages, faiths, beliefs, and walks of life to receive a personal blessing to the backdrop of world devotional music. Demprieys darshan can have profound transformational effects, which often evokes exalted states of bliss, kundalini rising and even healing of physical ailments.

During the one-day retreat, guests can immerse themselves in wisdom, grace, love and humor while receiving blessing and guidance to move into deeper levels of self-mastery. Throughout the day, participants will experience illuminating discourses and guided meditations. The retreat fee includes a vegan lunch.

For more information, pricing and registration for the one-day retreat, visit louix.org.

Read the original post:

This Darshan and one-day retreat in Eagle will bring spiritual awareness to all who attend - Vail Daily News

Panday honoured in Tobago by Spiritual Baptist – Trinidad Guardian

Shastri Boodan

Former prime minister Basdeo Panday was honoured on Saturday by the Tobago Circuit of the National Evangelical Spiritual Baptist Faith under the patronage of His Grace Archbishop Glenroy Jack.

Panday told the gathering at the Rovanels Resort and Conference Centre that he has not given up hope to see a nation united regardless of ethnic and cultural differences.

So that we can become the great nation that God intended us to be. he said.

Panday said the name Spiritual Shouter Baptist is unique to T&T as it is the only country to have a public holiday in its honour.

The former PM also gave an historical account of the decades of struggles of the Shouter Baptist movement to gain recognition.

He said his administration 1996-2001 also gave recognition to persons of the Orisha faith through the passing of the Orisha Marriage Act that legalised Orisha marriages in T&T.

He said the Orishas were treated in the same manner as the Hindus and Muslims under the British colonial government whose aim was to divide and rule the nation for the sake of power.

Panday later told Guardian Media that T&T is no closer to achieving the unity he dreams of because the constitution is causing the differences with people. He said unless constitutional reform takes place discrimination would always continue.

Panday also said he has no problem with a name change of the Piarco International Airport once the facility is operated with efficiently.

Continued here:

Panday honoured in Tobago by Spiritual Baptist - Trinidad Guardian

Institute for Priestly Formation puts spiritual lives of priests front and center – The Catholic Spirit

Auxiliary Bishop Andrew Cozzens talks with George Esseff of California, an emeritus member of the Institute for Priestly Formations Mission Advisory Council, during IPFs 25th anniversary celebration in July in Omaha, Nebraska. COURTESY FORD JACOBSEN

And it centered on a highly influential but, aside from those directly involved, little-known institute in Omaha, Nebraska.

The Institute for Priestly Formation, which this year is celebrating its 25th anniversary, offers retreats, spiritual direction and guidance, with a focus on seminarians and diocesan priests. Its offerings include a nine-week summer program on the campus of Creighton University, which this year attracted 177 seminarians from more than 60 U.S. dioceses, including five from the Archdiocese of St. Paul and Minneapolis.

The institute also conducts retreats for bishops and seminary theologians, days of reflection for laity, theological forums and other programs.

Bishop Cozzens estimates that about 40 priests of the archdiocese have gone through spiritual direction training at IPF. Others have benefited from retreats and taught summer courses at the institute.

Bishop Cozzens said he first heard about IPF as a priest of the archdiocese in 2006, when he started work in seminary formation. He went on a 30-day IPF silent retreat at Creighton in the summer of 2008.

I would say that the retreat was for me a very life-changing experience. I joke, sometimes, that for me theres been two lives, one was before the retreat and one was after the retreat. And the one after was a whole lot better than the one before.

That retreat, with silence and time to be alone with God, brought a new way for Bishop Cozzens to view himself and his daily life with the Lord.

You cant escape yourself, he said. You have to deal with yourself. And then you learn that that allows you to engage the world in a different way.

It gave me a desire to have that be part of my whole life, that I would always live in Gods presence, that I would always try to be with him.

That focus on spirituality and carving out time to develop it is critically important, Bishop Cozzens said. Seminaries are busy places where much is accomplished but time is limited, he said.

And as Priesthood Sunday approaches Sept. 29 this year, a day set aside by Serra International to honor priests and affirm the role of the priesthood in the life of the Church people might reflect on ways to support the spiritual lives of their pastors and other priests, Bishop Cozzens said.

There are many ways to advance spiritual development, not just IPF, the bishop said. But it could be said that IPF has had a greater impact on the seminarians and priests in the United States than almost any other organization in the last 25 years, in terms of the depth of their impact helping priests and seminarians appreciate and grow in a life of prayer and in the skills of spiritual direction, said Bishop Cozzens, who is on IPFs corporate board as treasurer as well as its bishops and mission advisory councils. Father Joseph Taphorn, a native of Omaha who has been involved as a spiritual director with IPF and in January began serving as rector of The St. Paul Seminary School of Divinity, said it wasnt the case before, but now the archdiocese is asking its seminarians to attend an IPF summer session as they enter their studies at the graduate level seminary.

It gives a man an opportunity to have a very intentional and focused relationship with our Lord, Father Taphorn said of the sessions, which begin with an eight-day silent retreat. Its a chance to say, this is what were about this summer.

Father Jonathan Kelly, who teaches at the undergraduate St. John Vianney College Seminary in St. Paul, has been on two, 30-day retreats at the institute, in 2007 and 2017. He also has taught at IPF and helped direct the 30-day retreats, which he calls transformational.

Transformational is the Lord doing the work and speaking to us in a way that well never forget, Father Kelly said. The silence of a 30-day retreat and a good spiritual director (guiding the retreat) who stays silent, who might see it but waits for the Lord to say it, that is transformational.

As priests and seminarians develop their spiritual lives, they can help others grow in similar fashion, Bishop Cozzens said.

It really helps priests strengthen their own identity as a spiritual father and as a spiritual director as they serve in the priesthood, Bishop Cozzens said.

They (IPF) teach people how to bring their real lives into relationship with God, and that affects a mans preaching, that affects the way a man cares for people in very positive ways, Bishop Cozzens said. Its why we want our seminarians when possible to go through at an early stage, so that they early on begin to recognize that their lives are being brought into this relationship with God. And then they can help others to do that.

Tags: Priestly formation

Category: Local News

Read the original:

Institute for Priestly Formation puts spiritual lives of priests front and center - The Catholic Spirit

AI Pinpoints Genes Associated With Heart Failure – Forbes

While AI may increase speed and efficiency of medical care on the front lines, one of its most powerful benefits is the ability to search vast amounts of data to learn about genetic aspects of various diseases.

Cardiomegaly Is An Enlargement Of The Heart Due To Dilatation Of The Heart Cavities. This Can Result ... [+] From Many Conditions Including A Disease Of The Heart Muscle Myocardial Disease, Defective Valve Function, Or Hypertrophy Of The Heart Muscle Due To Stenosis Of The Aortic Valve. Pericardial Effusion Fluid Collection In The Fibrous Envelope Of The Heart Can Also Lead To Considerable Cardiomegaly Visible On The X Ray. Left Untreated, Cardiomegaly Can Lead To Heart Failure Characterized By Dyspnea Difficulty Breathing And Edema Of The Lower Limbs. (Photo By BSIP/UIG Via Getty Images)

Earlier identification of persons at risk for heart failure or a genetic cardiomyopathy is a prime example. This could enable persons to be more closely monitored by health care providers and even placed on lists for transplant before they decompensate and develop heart failure leading to cardiogenic shock, which can be ultimately be fatal if not treated and identified in a timely fashion.

Researchers at Queen Mary University of London have now harnessed the power of AI to identify patients who are at risk for heart failure, enabling earlier identification, management and treatment of these high-risk individuals.

The research team used an artificial intelligence (AI) technique to analyze cardiac MRI images of 17,000 healthy UK Biobank volunteers. They noted that genetic factors accounted for 22-39% of variation in the size and function of the left ventricle (LV), the main chamber in the heart that pumps blood to the rest of the body. Reduced pumping ability and increase in size of the left ventricle leads to heart failure.

The research, recently published in the journalCirculation, highlights the importance of genetic factors and their role in the contribution to structural heart disease. The investigators discovered 14 specific areas (loci) linked to the dimensions, structure and function of the left ventricle containing genes that control the embryonic development of heart chambers and the contraction of heart muscle.

"It is exciting that the state-of-the-art AI techniques now allow rapid and accurate measurement of the tens of thousands of heart MRI images required for genetic studies, said lead researcher Dr. Nay Aung from Queen Mary University of London in a press release. The findings open up the possibility of earlier identification of those at risk of heart failure and of new targeted treatments; the genetic risk scores established from this study could be tested in future studies to create an integrated and personalized risk assessment tool for heart failure.

"The AI tool allowed us to analyze images in a fraction of the time it would otherwise have taken; this should translate to time and cost savings for the NHS and could potentially improve the efficiency of patient care, he added.

"Previous studies have shown that differences in the size and function of the heart are partly influenced by genes but we have not really understood the extent of that genetic influence,explained co-investigator Steffen Petersen, Professor of Cardiovascular Medicine at Queen Mary University of London. This study has shown that several genes known to be important in heart failure also appear to regulate the heart size and function in healthy people.

That understanding of the genetic basis of heart structure and function in the general population improves our knowledge of how heart failure evolves; the study provides a blueprint for future genetic research involving the heart MRI images in the UK Biobank and beyond, he added.

"High fidelity MRI measures combined with genetics is reassuringly validating many known heart structural proteins, but our work also finds new genes from more heritable functional measures that are associated with ventricular remodeling and fibrosis, added co-investigator Patricia Munroe, Professor of Molecular Medicine at Queen Mary University of London. Further genetic studies including analyses of additional heart MRI chambers are expected to provide deeper insights into heart biology."

In fact, identification of specific genes that play a role in determining left ventricular volume, a key marker of survival in the setting of heart failure (resulting from LV remodeling in the setting of a cardiomyopathy), would be quite valuable. The advent of gene therapy, progenitor cell therapy (stem cells) and emerging molecular genetic approaches to address these genetic anomalies may offer promise.

With the expansion of the UK Biobank database, the expectation is that more genes for cardiac abnormalities will be notified in the future. In fact, UK Biobank announced earlier this month that it will begin sequencing the entire human genome of 450,000 participants, after success of a pilot sequencing trial in 50,000 participants.

Read the rest here:

AI Pinpoints Genes Associated With Heart Failure - Forbes

Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment…

Basel, 30 September 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will today announce positive results from a single-arm cohort of the Phase II/III Blood First Assay Screening Trial (BFAST), the first prospective study to use only blood-based next generation sequencing (NGS) to detect specific fusions with the aim of selecting treatment for people with advanced non-small cell lung cancer (NSCLC), without the need for tissue biopsy. Results from the anaplastic lymphoma kinase (ALK) cohort will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress on Monday 30 September 2019, from 9:15 - 9:30 am CEST (Abstract LBA81 PR), and were also part of the official ESMO press programme.

Obtaining tumour tissue for biomarker testing can be a challenge in many people with cancer and, as a result, some may not receive optimal treatment for their disease, said Sandra Horning, MD, chief medical officer and head of Global Product Development. BFAST is the first trial to show that by using a blood-based next-generation diagnostic, it is possible to identify the ALK mutation in people with non-small cell lung cancer using a blood draw alone, which means that more people could potentially benefit from Alecensa.

Foundation Medicine is pleased to partner with Roche on this study, a first-of-its-kind, pivotal trial that directly demonstrates the clinical utility of using our comprehensive blood-based assay, FoundationOne Liquid, to detect specific fusions and match NSCLC patients with first-line treatment, said Brian Alexander, MD, chief medical officer of Foundation Medicine. Validated and comprehensive liquid biopsy tests are critical to help physicians find the best possible treatment approach for patients with advanced cancer and for whom tissue testing isnt feasible. Identifying ALK fusions can be particularly challenging and these data demonstrate that FoundationOne Liquid can accurately predict which patients can respond to therapy.

The BFAST study used FoundationOne Liquid, Foundation Medicines comprehensive liquid biopsy test, which detects the four main classes of genomic alterations, microsatellite instability (MSI) and select fusions including ALK in circulating tumour DNA (ctDNA) from a blood draw. These data demonstrate that the FoundationOne Liquid assay can help to test and identify a broader population of people with advanced NSCLC who may benefit from Alecensa (alectinib), for whom current diagnostic tests are not suitable, such as for those who cannot provide tissue samples due to insufficient or absent tumour tissue or where tissue diagnostics are not available, and validate the clinical utility of blood-based NGS as an additional method to inform clinical decision-making in ALK-positive NSCLC.

In the study, 87.4% (95% CI: 78.5-93.5) of people with advanced NSCLC who were identified by the FoundationOne Liquid biopsy assay to have ALK fusions had a confirmed response to treatment with Alecensa (overall response rate; ORR) as measured by the investigator per Response Evaluation Criteria in Solid Tumours (RECIST v1.1). This is consistent with the ORR for Alecensa observed in the pivotal Phase III ALEX trial, which identified people using tissue-based testing. When measured using an Independent Review Facility per RECIST v1.1, the confirmed ORR was numerically higher at 92.0% (95% CI: 84.1-96.7). Median progression free-survival (PFS) and duration of response (DoR) were not reached after a median follow-up of 12.6 months. The safety profile of Alecensa was consistent with prior clinical trials and post-marketing experience, with no new safety signals observed.

About the BFAST Study BFAST (Blood First Assay Screening Trial; NCT03178552) is a Phase II/III global, multi-centre, open label, multi-cohort study evaluating the safety and efficacy of targeted therapies or immunotherapies as single agents or in combination in people with unresectable, advanced or metastatic NSCLC determined to harbour oncogenic somatic mutations or be tumour mutational burden (TMB) positive as identified by blood-based NGS ctDNA assays. The Alecensa ALK-positive cohort is the first to readout, with other cohorts due to follow. The primary endpoint for the Alecensa ALK-positive cohort of the BFAST study is confirmed investigator (INV)-assessed ORR. Secondary endpoints include: independent review facility (IRF)-assessed ORR, DoR (INV and IRF), PFS (INV and IRF), overall survival (OS) and safety.

About AlecensaAlecensa (RG7853/AF-802/RO5424802/CH5424802) is a highly selective, CNS active, oral medicine created at Chugai Kamakura Research Laboratories and is being developed for people with NSCLC whose tumours are identified as ALK-positive. ALK-positive NSCLC is often found in younger people who have a light or non-smoking history. It is almost always found in people with a specific type of NSCLC called adenocarcinoma. Alecensa is now approved in 83 countries as an initial (first-line) treatment for ALK-positive, metastatic NSCLC, including in the US, Europe, Japan and China.

About Foundation Medicine Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company, a member of the Roche Group, offers a full suite of comprehensive genomic profiling tests to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicines molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.

For more information, please visit http://www.foundationmedicine.com or follow Foundation Medicine on Twitter (@FoundationMedicineATCG).

About Roche in lung cancerLung cancer is a major area of focus and investment for Roche, and we are committed to developing new approaches, medicines and tests that can help people with this deadly disease. Our goal is to provide an effective treatment option for every person diagnosed with lung cancer. We currently have five approved medicines to treat certain kinds of lung cancer and more than ten medicines being developed to target the most common genetic drivers of lung cancer or to boost the immune system to combat the disease.

About RocheRoche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve peoples lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the worlds largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit http://www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Group Media RelationsPhone: +41 61 688 8888 / e-mail: media.relations@roche.com- Nicolas Dunant (Head)- Patrick Barth- Ulrike Engels-Lange- Daniel Grotzky- Karsten Kleine- Nathalie Meetz- Barbara von Schnurbein

Story continues

See the original post here:

Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment...

Skin-Cells-Turned-to-Heart-Cells Help Unravel Genetic Underpinnings of Cardiac Function – UC San Diego Health

By examining heart cells derived from the skin samples of seven family members, researchers at UC San Diego School of Medicine discovered that many genetic variations known to influence heart function do so because they affect the binding of a protein called NKX2-5.

Genome-wide association studies have uncovered more than 500 genetic variants linked to heart function, everything from heart rate to irregular rhythms that can lead to stroke, heart failure or other complications. But since most of these variations fall into areas of the genome that dont encode proteins, exactly how they influence heart function has remained unclear.

By examining heart cells derived from the skin samples of seven family members, researchers at University of California San Diego School of Medicine have now discovered that many of these genetic variations influence heart function because they affect the binding of a protein called NKX2-5.

The study is published September 30, 2019 in Nature Genetics.

NKX2-5 is a transcription factor, meaning it helps turn on and off genes in this case, genes involved in heart development. To do this, NKX2-5 must bind to non-coding regions of the genome. Thats where genetic variation comes in.

NKX2-5 binds to many different places in the genome near heart genes, so it makes sense that variation in the factor itself or the DNA to which it binds would affect that function, said senior author Kelly A. Frazer, PhD, professor of pediatrics and director of the Institute for Genomic Medicine at UC San Diego School of Medicine. As a result, we are finding that multiple heart-related traits can share a common mechanism in this case, differential binding of NKX2-5 due to DNA variants.

The study started with skin samples from seven people from three generations of a single family. The researchers converted the skin cells into induced pluripotent stem cells (iPSCs) as an intermediary. Like all stem cells, iPSCs can both self-renew, making more iPSCs, and differentiate into a specialized cell type. With the right cocktail of molecules and growth factors, the researchers directed iPSCs into becoming heart cells.

These heart cells actually beat in the laboratory dish, and still bear the genetic and molecular features of the individuals from which they were derived.

Frazer and team conducted a genome-wide analysis of these patient-derived heart cells. They determined that NKX2-5 can bind approximately 38,000 sites in the genome. Of those, 1,941 genetic variants affected NKX2-5 binding. The researchers investigated the role of those variants in heart gene function and heart-related traits. One of the genetic variants was associated with the SCN5A gene, which encodes the main channel through which sodium is transported in heart cells.

Since related individuals tend to share similar genetic variants, the team was able to validate their findings by analyzing the same variants in multiple samples.

People typically need a large number of samples to detect the effects of common DNA variants, so we were surprised that we were able to identify with high confidence these effects on NKX2-5 binding at so many sites across the genome with just few people, said first author Paola Benaglio, PhD, a postdoctoral researcher in Frazers lab.

Yet, she said, this finding may just be the tip of the iceberg.

There are probably a lot more genetic variants in the genome involved with NKX2-5 as well as with other important cardiac transcription factors, Frazer said. We identified almost 2,000 in this study, but thats probably only a fraction of what really exists because we were only looking at seven people in a single family and only at one transcription factor. There are probably many more variants in gene regulation sites across the entire population.

Not only does the team plan to further investigate cardiovascular genetics, they also have their sights set on other organ systems.

We are now expanding this same model system to look at many different transcription factors, across different tissue types, such as pancreas and retina epithelia, and scaling it up to include more families, Benaglio said.

Co-authors include: Agnieszka DAntonio-Chronowska, William W. Young Greenwald, Margaret K. R. Donovan, Christopher DeBoever, He Li, Frauke Drees, Sanghamitra Singhal, Hiroko Matsui, Kyle J. Gaulton, Erin N. Smith, Matteo DAntonio, Michael G. Rosenfeld, UC San Diego; Wubin Ma, Feng Yang, Howard Hughes Medical Institute and UC San Diego; Jessica van Setten, University Medical Center Utrecht; and Nona Sotoodehnia, University of Washington.

This research was funded, in part, by the National Institutes of Health (grants HG008118, HL107442, F31HL142151, T32GM008666, P30CA023100, HL116747, HL141989, R01DK114650, DK018477, DK039949), National Science Foundation (grant 1728497), California Institute for Regenerative Medicine (grants GC1R-06673-B, TG2-01154), Swiss National Science Foundation (postdoc mobility fellowships P2LAP3-155105,P300PA-167612), ADA (grant 1-17-JDF-027) and Howard Hughes Medical Institute.

UC San Diegos Studio Ten 300 offers radio and television connections for media interviews with our faculty. For more information, email .(JavaScript must be enabled to view this email address).

See the original post here:

Skin-Cells-Turned-to-Heart-Cells Help Unravel Genetic Underpinnings of Cardiac Function - UC San Diego Health

$1.68 Billion Molecular Diagnostics Point of Care Market – Global Analysis and Forecast, 2019-2029 – Yahoo Finance

DUBLIN, Sept. 30, 2019 /PRNewswire/ -- The "Global Molecular Diagnostics Point of Care Market: Focus on Application, Technology, Type, End User, Country Data (15 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2029" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global molecular diagnostic point of care industry analysis projects the market to grow at a significant CAGR of 12.14% during the forecast period, 2019-2029. The molecular diagnostic point of care market generated $1,689.6 million revenue in 2018, in terms of value.

Key Questions Answered in this Report:

The molecular diagnostic point of care market growth has been primarily attributed to the major drivers in this market such as highly increasing global prevalence of infectious diseases and various types of cancer, growing demand for non-invasive diagnostics, increase in adoption of personalized medicines on a global level, and significant external funding for executing research and development exercises. The challenges include an uncertain reimbursement scenario, a lack of high-complexity testing centers, and high capital requirement hampering the global reach.

Scope of the Market Intelligence on Global Molecular Diagnostic Point of Care Market

The molecular diagnostic point of care research provides a holistic view of the market in terms of various factors influencing it, including regulatory reforms, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the diagnostic market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, the growth potential of each underlying sub-segment, and company, as well as other vital information with respect to the global molecular diagnostic point of care market.

Market Segmentation

Market Dynamics

Market Drivers

Market Restraint

Market Opportunities

The key manufacturers who have been contributing significantly to the molecular diagnostic point of care market include

For more information about this report visit https://www.researchandmarkets.com/r/wfpdj4

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/1-68-billion-molecular-diagnostics-point-of-care-market---global-analysis-and-forecast-2019-2029--300927707.html

Read more:

$1.68 Billion Molecular Diagnostics Point of Care Market - Global Analysis and Forecast, 2019-2029 - Yahoo Finance

UT Health working to fight children’s cancer with Hyundai Hope on Wheels grant – KENS5.com

SAN ANTONIO UT Health San Antonio is fighting children's cancer in a partnership with Hyundai Hope on Wheels.

To help in the fight against pediatric cancer, Hyundai Hope on Wheels presented two grants totaling $500,000 to UT Health San Antonio for pediatric cancer research Tuesday.

Gregory Aune, M.D., Ph.D., associate professor of pediatric hematology-oncology and an investigator in the Greehey Institute, will receive a $300,000 Hyundai Scholar Hope Award.

The Aune team will test a hypothesis that a particular cell type in the heart is possibly a major contributor to the long-term cardiac toxicity seen in childhood cancer survivors, the press release says.

Amanda Lipsitt, M.D., a third-year fellow in pediatric hematology-oncology, will receive a $200,000 Hyundai Young Investigator Award.

Dr. Lipsitt is studying angiosarcoma, a rare but aggressive form of cancer seen in both children and adults. She is conducting the research in a zebrafish cancer model, the press release says.

The grants will allow both physician-scientists to continue their research into better treatment options, working to eliminate childhood cancer.

Children were able to enjoy the event with finger painting a new Hyundai SUV and taking a laboratory tour.

UT Health San Antonio

UT Health San Antonio

These new research grants provided by Hyundai Hope on Wheels represent a new chapter of hope for children and parents said Peter Houghton, Ph.D., professor of molecular medicine and director of the Greehey Institute.

Link:

UT Health working to fight children's cancer with Hyundai Hope on Wheels grant - KENS5.com

Mergers & Acquisitions in the Global IVD Market, 2019 – Leading Players are Roche, Abbott and Danaher – Yahoo Finance

Dublin, Oct. 01, 2019 (GLOBE NEWSWIRE) -- The "Mergers and Acquisitions in the IVD Market" report has been added to ResearchAndMarkets.com's offering.

In vitro diagnostic (IVD) products continue to see positive sales growth in many categories. New products, changes in global health spending, regulatory changes in major markets and disease trends are among the factors that produce a constantly changing market picture.

In this environment, companies are making strategic acquisitions that simultaneously add a revenue stream and product innovation.

The report looks at these market transactions in Mergers and Acquisitions in the IVD Market, recording more than 220 acquisitions in the diagnostics industry from 2016 to June 2019.

Though some segments of the overall IVD market are still relatively small, they represent the biggest growth areas in the market. The report focuses on acquisitions in these growing segments of great market interest, anticipated to be a big part of the future of IVD, including the following:

The merger and acquisition activities of major players in the market are of course of interest as well, therefore the report provides detailed discussion of activities of leading companies, including:

Detailed listings of company buys are featured in the report:

From 2018 to 2019, the report provides summaries of the market impact of numerous transactions, including:

From 2016 to 2017, the report provides summaries of the market impact of numerous transactions, including:

Key Topics Covered

1: Executive Summary

2: IVD Mergers and Acquisitions

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/jsk83

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Originally posted here:

Mergers & Acquisitions in the Global IVD Market, 2019 - Leading Players are Roche, Abbott and Danaher - Yahoo Finance

Doors Open Day Edinburgh: Each of the 137 venues you can look around this weekend – Edinburgh Live

More than 130 of Edinburgh's most interesting buildings will be opening their doors to the public this weekend.

Doors Open Day will be taking place on Saturday and Sunday (September 28 and 29).

Edinburgh Live reported this week that Leith Police Station, housed in the old court and town hall, is among the venues opening. People will be able to access the striking building on Queen Charlotte Street from 10am to 4pm on Sunday.

A number of venues such as The Playfair at Donaldsons, Barnton Quary ROTOR Bunker and Torness Nuclear Power Station are already fully booked, but there are plenty of other amazing places you can visit across the weekend.

A full list can be found below. To book a spot, or for further information on the events, visit the Doors Open Day website by clicking here.

603 (City of Edinburgh) Squadron, Royal Auxiliary Air Force (28-29 September)

Abbeyhill Baptist Church (28 September)

Abden House, The Confucius Institute (28 September)

Advocates Library (28 September)

Anatomical Museum (28 September)

Appleton Tower: School of Infomatics (28 September)

Arthur Conan Doyle Centre (28-29 September)

Assembly Rooms (28 September)

Astley Ainslie Hospital (28-29 September)

Astoria Centre (29 September)

Augustine United Church (28-29 September)

Barnton Quarry ROTOR Bunker (28-29 September)

Bayes Centre (29 September)

Bellfield (29 September)

Bridgend Farmhouse (29 September)

Buccleuch & Greyfriars Free Church of Scotland (28 September)

Burns Monument (28-29 September)

Canongate Kirk & Kirkyard (28-29 September)

Castle Mills (Edinburgh Printmakers) (28-29 September)

Chalmers Church (28 September)

Chapel of St Albert the Great (28-29 September)

Chapel of St John (28-29 September)

Charlotte Chapel (28 September)

Church of the Sacred Heart (28 September)

Cockburn Association (28-29 September)

Collective, City Observatory, Calton Hill (28-29 September)

Corstorphine Hill Tower (28-29 September)

Cottage, West Princes Street Gardens (28-29 September)

Craigsbank Parish Church (28-29 September)

Custom House Leith (28 September)

Dean Gardens (29 September)

Dovecot Studios (28 September)

Dower House (28 September)

Drumsheugh Baths Club (28 September)

Edinburgh Baha'i Centre (28 September)

Edinburgh Law School, Old College (28 September)

Edinburgh Sculpture Workshop (28 September)

Edinburgh Sheriff and Justice of the Peace Court (28 September)

Festival Theatre Edinburgh (28 September

Fountainbridge Library (28 September)

Georgian Antiques (29 September)

Gogar Cabinet Works (28-29 September)

Granton Castle Walled Garden (28 September)

Greyfriars Kirk (28-29 September)

Grove Community Garden (28 September)Harlaw House Visitor Centre (28 September)

Harmeny School (29 September)

Herbarium & Library Building - Royal Botanic Gardens (28 September)

Inch House Community Centre (29 September)

Informatics Forum (29 September)

Institut Francais D'Ecosse (28-29 September)

Institution of Civil Engineers (ICE) Scotland Museum (28 September)

James Clerk Maxwell Foundation (28 September)

JM Architects (28 September)

John Knox House (28 September)

Kings Theatre Edinburgh (29 September)

King's Buildings (28 September)

Leith Theatre (29 September)

Leith Town Hall & Sheriff Court (29 September)

Lothian Buses (28 September)

Magdalen Chapel (28 September)

Mayfield Salisbury Parish Church of Scotland (28 September)

Meadows Croquet Club (28 September)

Morningside Cemetary (28 September)

MRC Institute of Genetics and Molecular Medicine (28 September)

National Galleries of Scotland - Granton Art Centre (28 September)

National Library of Scotland (28 September)

National Library of Scotland (Causewayside) (28 September)

National Museums Collection Centre - SOLD OUT (28 September)

New Register House (28 September)

Newington Cemetery (29 September)

North Edinburgh Arts Garden (28 September)

Northern Lighthouse Board (28-29 September)

Oakvale Funeral Home (28-29 September)

Old College, University of Edinburgh (28-29 September)

Oriam - Scotland's Sports Performance Centre (28 September)

Out of the Blue Drill Hall (29 September)

Panmure House (29 September)

Parish Church of St Cuthbert (28 September)

Playfair at Donaldsons (29 September)

Police Box (28 September)

Portobello Baptist Church (28 September)

Priory Church of St Mary of Mount Carmel (28-29 September)

Queen Street Gardens Central and East Districts (28 September)

Queen's Nursing Institute Scotland (28 September)

Queensferry Parish Church (28 September)

Ramp House (29 September)

Ratho Byres Forge (28-29 September)

Redhall Walled Garden (SAMH) (28 September)

Regent, Royal and Calton Terrace Gardens (29 September)

Riddle's Court (28-29 September)

Royal Observatory Edinburgh (28-29 September)

Scottish Arts Club (28-29 September)

Scottish Free French House, Official Residence of the Consul General of France (28-29 September)

Scottish Mineral and Lapidary Club (28-29 September)

Seafield Treatment Centre - Veolia (28-29 September)

Original post:

Doors Open Day Edinburgh: Each of the 137 venues you can look around this weekend - Edinburgh Live

Drive high CAGR by Global Bioinformatics Market Along with Top Key Players like Life Technologies, Illumina, Inc., Agilent Technologies and Active…

Global Bioinformatics Market Industry Analysis:Bioinformatics is the combination of biology and information technology. It is used widely in the management of biological information in the field of medical research and development of drugs. It uses computer software tools for database creation, data management, data warehousing, data mining and communication networking. Bioinformatics deals with the recording, annotation, storage, analysis and retrieval of nucleic acid sequence, protein sequence and structural information. It has several applications in the fields of medicine and biology including molecular medicines, preventive medicines, gene therapy, drug developments, biotechnology and forensic analysis of microbes. It is also used in the study of genetics and genomes.

The Bioinformatics market research study relies upon a combination of primary as well as secondary research. It throws light on the key factors concerned with generating and limiting Bioinformatics Market growth. In addition, the current mergers and acquisition by key players in the market have been described at length. Additionally, the historical information and growth in the CAGR have been given in the research report. The latest trends, product portfolio, demographics, geographical segmentation, and regulatory framework of the Bioinformatics market have also been included in the study.

Sample of this Report: https://www.acquiremarketresearch.com/sample-request/201553/

The Global Bioinformatics Market Can Be Segmented As

Top key Players: Life Technologies, Illumina, Inc., Agilent Technologies and Active Motif, Inc., Bio-Rad LaboratoriesQIAGEN, Knome, Inc., GE Healthcare, Quest Diagnostics ,

ProductKnowledge Management Tools, Data Analysis Platforms ,

Product Application Genomics, Chemoinformatics and Drug Design, Proteomics, Transcriptomics, Metabolomics, Others ,

The research report on the Global Bioinformatics Market is a comprehensive study of the current scenario of the market, covering the key market dynamics. The report also provides a logical evaluation of the key challenges faced by the leading pioneers operating in the market, which helps the participants in understanding the difficulties they may face in future while functioning in the global market over the forecast period.

To get this report at beneficial rates: https://www.acquiremarketresearch.com/discount-request/201553/

The Bioinformatics industry research report studies the production, supply, sales, and the current status of the market in a profound manner. Furthermore, the report studies the production shares and market product sales, as well as the capacity, production capacity, sales, and revenue generation. Several other factors such as import/export status, demand, supply, gross margin, and industry chain structure have also been studied in the Global Bioinformatics Market report.

This study gives data on patterns and improvements, and spotlights on Markets and materials, limits and on the changing structure of the Bioinformatics Industry. The key motivation behind the report is to give a proper and key examination of this industry.

Get More Details @https://www.acquiremarketresearch.com/industry-reports/bioinformatics-market/201553/

Reasons to buy this report:

Understand the current and future of the Keyword Market in both developed and emerging markets.

The report assists in realigning the business strategies by highlighting the Keyword business priorities.

The report throws light on the segment expected to dominate the Keyword industry and market.

Forecasts the regions expected to witness the fastest growth.

In the end, Bioinformatics Market Report delivers a conclusion which includes Breakdown and Data Triangulation, Consumer Needs/Customer Preference Change, Research Findings, Market Size Estimation, Data Source. These factors will increase the business overall.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like Asia, United States, Europe.

See the rest here:

Drive high CAGR by Global Bioinformatics Market Along with Top Key Players like Life Technologies, Illumina, Inc., Agilent Technologies and Active...

Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated RET-Altered Thyroid Cancers | Small Molecules | News…

DetailsCategory: Small MoleculesPublished on Tuesday, 01 October 2019 13:24Hits: 111

- LIBRETTO-001 is the largest trial ever reported in RET-altered cancer patients

- 56 percent objective response rate (ORR) in the registration dataset (n=55) of RET-mutant medullary thyroid cancer (MTC) patients who had previously received cabozantinib and/or vandetanib

- 59 percent ORR in cabozantinib/vandetanib-nave RET-mutant MTC patients

- 62 percent ORR in heavily pretreated RET fusion-positive thyroid cancer patients

- Sustained durability, measured by both Duration of Response and Progression-Free Survival

- Well-tolerated safety profile; low rate of discontinuation (1.7%) for treatment-related adverse events

- New Drug Application to be submitted by year-end

INDIANAPOLIS, IN, USA I September 29, 2019 I Eli Lilly and Company (NYSE: LLY) today presented data from the LIBRETTO-001 clinical trial intended to support the registration of oral selpercatinib1 monotherapy, also known as LOXO-292, for the treatment of RET-altered thyroid cancers. RET-altered thyroid cancers are comprised of two different populations, RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancers. In the RET-mutant MTC registration dataset consisting of the first 55 enrolled patients with prior cabozantinib and/or vandetanib2, selpercatinib treatment resulted in a 56 percent objective response rate (ORR) (95% CI: 42-70%). This population was heavily pretreated (53 percent previously treated with 2 prior multikinase inhibitors), and ORR was similar regardless of prior multikinase inhibitor therapy. As of the data cut-off date of June 17, 2019, median duration of response (DOR) was not reached (95% CI: 11.1-NE) and median progression-free survival (PFS) was not reached (95% CI: 11.3-NE). Selpercatinib therapy also resulted in robust biochemical response rates (BRR) for serum tumor markers calcitonin (91% BRR) and carcinoembryonic antigen (64% BRR). In a safety analysis of all 531 patients enrolled to LIBRETTO-001, selpercatinib was well-tolerated, with only nine patients (1.7%) discontinuing therapy due to treatment-related adverse events. The most commonly observed adverse events, regardless of attribution, were dry mouth, diarrhea, hypertension, increased liver enzymes, fatigue, constipation, and headache. These results were presented today at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona, Spain, in session LBA93, Registrational Results of LOXO-292 in Patients with RET-Altered Thyroid Cancers, presented by Lori J. Wirth, M.D., medical director of head and neck cancers, Massachusetts General Hospital Cancer Center in Boston, Mass. Selpercatinib has received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA).

"Current therapeutic options are often challenging for patients with first-line RET-altered thyroid cancers and are limited for patients who relapse. The data for selpercatinib show demonstrative efficacy and safety in both the first-line and relapsed settings. Patients with thyroid cancer have long sought targeted therapy tailored to the molecular nature of their disease, and we are hopeful that selpercatinib may be used as the standard of care in the future," said Wirth, who is lead investigator on the trial.

Selpercatinib Data in Cabozantinib/Vandetanib-Nave RET-Mutant MTC patientsInvestigators also presented the results of selpercatinib in RET-mutant MTC patients who have received neither cabozantinib nor vandetanib. In this analysis of 76 patients, selpercatinib treatment resulted in a 59 percent ORR (95% CI: 47-70%). Median DOR and PFS were not reached in this treatment-nave population, as the vast majority of patients remain in response or progression-free.

Selpercatinib Data in Heavily Pretreated RET Fusion-Positive Thyroid Cancer PatientsInvestigators also presented the results of selpercatinib in heavily pretreated RET fusion-positive thyroid cancer patients. In this analysis of 26 patients, selpercatinib treatment resulted in a 62 percent ORR (95% CI: 41-80%). Median DOR and PFS were not reached in this population, as the vast majority of patients remain in response or progression-free.

"We're pleased that selpercatinib may offer a meaningful advance for patients with RET-altered thyroid cancers," said Anne White, president of Lilly Oncology. "These patients have been a focus of the selpercatinib program from its beginning, as RET has been a known oncogene in these diseases for decades. With these data, selpercatinib has delivered on our vision, with unprecedented clinical outcomes in both first-line and relapsed patients, particularly in light of the difficult options for these patients."

Trial BackgroundThe LIBRETTO-001 Phase 1/2 trial is the largest clinical trial of patients with RET-altered cancers treated with a RET inhibitor. The trial includes a dose escalation phase (Phase 1) and a dose expansion phase (Phase 2). The Phase 2 portion of the trial had a primary endpoint of objective response rate (ORR) and secondary endpoints of DOR, PFS and safety. The primary analysis set for MTC regulatory submissions, as defined with the FDA, consists of the first 55 enrolled patients with RET-mutant medullary thyroid cancer who have experienced prior cabozantinib and/or vandetanib. All data presented at ESMO were as of a data cut-off date of June 17, 2019, and all efficacy measures utilized investigator assessments.

About Selpercatinib (LOXO-292)Selpercatinib, also known as LOXO-292, is a highly selective and potent, oral investigational new medicine in clinical development for the treatment of patients with cancers that harbor abnormalities in the rearranged during transfection (RET) kinase. RET fusions and mutations occur across multiple tumor types with varying frequency. Selpercatinibwas designed to inhibit native RET signaling as well as anticipated acquired resistance mechanisms.

Selpercatinib has received breakthrough designation for the treatment of patients with:

About RET-Altered CancersGenomic alterations in RET kinase, which include fusions and activating point mutations, lead to overactive RET signaling and uncontrolled cell growth. RET fusions have been identified in approximately 2 percent of non-small cell lung cancer, 10-20 percent of papillary and other thyroid cancers and a subset of other cancers. Activating RETpoint mutations account for approximately 60 percent of MTC. RET fusion cancers and RET-mutant MTC are primarily dependent on this single activated kinase for their proliferation and survival. This dependency, often referred to as "oncogene addiction," renders such tumors highly susceptible to small molecule inhibitors targeting RET.

About Lilly OncologyFor more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly's commitment to people with cancer, please visit http://www.LillyOncology.com.

About Eli Lilly and CompanyLilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom. P-LLY

1PINN, pending USAN approval2The multikinase inhibitors, cabozantinib and vandetanib, are both FDA-approved for the treatment of progressive and metastatic medullary thyroid cancer regardless of RET mutation status.

SOURCE: Eli Lilly

See the rest here:

Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated RET-Altered Thyroid Cancers | Small Molecules | News...

Artificial Intelligence Is Being Used To Diagnose Disease And Design New Drugs – Forbes

Medical technology concept. Medical instruments.

The healthcare industry has always been a leader in innovation. The constant mutating of diseases and viruses makes it difficult to stay ahead of the curve, but with the help of artificial intelligence and machine learning algorithms, it continues to advance, creating new treatments and helping people live longer and healthier lives.

A study published this week by The Lancet Digital Health compared the performance of deep learninga form of artificial intelligence (AI)in detecting diseases from medical imaging versus that of healthcare professionals, using a sample of studies carried out between 2012 and 2019.

The study found that, in the past few years, AI has become more accurate of identifying disease diagnosis in these images and has become a more viable source of diagnostic information. According to the researchers, out of 14 studies that compared deep learning models and healthcare professionals within the same sample, the diagnostic performances were found to be equivalent.

With advances in AI, deep learning may become even more efficient in identifying diagnosis in the next few years.

AI applications in the field of healthcare arent just limited to diagnosing a disease, they also include its possible treatment.

Pharmaceutical company Bayer has recently been working with tech companies to create software to help diagnose complex and rare conditions and help develop new drugs to treat these diseases. They have been working in partnership with hospitals and researchers to determine what the machine learning needs to analyze to learn how to diagnose a patients medical condition. The information that the AI is absorbing comes from a number of factors from symptom data, disease causes, test results, medical images, doctor reports and more.

We can model how it will behave in a cell in combination with other drugs the patients might be taking. Were looking at how we can identify the right patients and sites to run our clinical trials. We would be able to run shorter studies and show where the medication is the right one for those patients earlier, Angeli Moeller, who heads artificial intelligence projects at Bayer, explained to the Associated Press.

The machine learning systems are not to replace doctors or make absolute decisions in a patients treatment. According to Moeller, they still want the patient to have control over their treatments and want to use the artificial intelligence to support decisions and make recommendations based on the findings.

Bayer is not the only company making waves in healthcare with AI. There are many other startup companies that are tackling AI treatment options for disease. According to BenchScislatest report ,there are currently 148 startups using artificial intelligence in drug discovery.

One of those startups, Atomwise, just partnered with Jiangsu Hansoh Pharmaceutical Group in a $1.5 billion dollar joint-venture operation to collaborate on designing new drugs for cancer treatments.

The partnership combines Atomwises artificial intelligence technology with Hansoh Pharmas manufacturing capabilities in order to work together to design new ways to predict how a small molecule will bind to a target protein and hopefully lead to new advancements in medical treatments. These joint-ventures are promising as it combines two essential elements for advancements in both machine learning and medical device innovation.

A Canadian biotech company, Deep Genomics, has been experimenting with machine learning and drug development for the past 5 years. Specifically they have been testing different treatments for a rare genetic disorder named Wilson Disease that currently has no treatments on the market. The disease prevents the body from removing copper that eventually builds up in the organs and can cause life-threatening organ damage and sometimes failure.

Deep Genomics artificial intelligence system discovered that the mutation changes an amino acid in ATP7B, a copper-binding protein that is absent in Wilson patients, and causes a disruption in the genome that causes that protein not to be produced. They are currently testing their drug on their first candidate in the study and hopeful this will be successful in treating the disease.

As of today, there are not any drug treatments on the market that were created by AI, but many companies are working hard to see that happen soon. The collection of patient data and testing will continue to drive advancements forward, and while these are great strides in the advancements of artificial intelligence working with medical professionals to save lives, it is far from being mainstream.

Its probably going to take two years before it really hits mainstream medical practice. Getting the technology to the patient is still the hard part, Moeller to the AP.

More here:

Artificial Intelligence Is Being Used To Diagnose Disease And Design New Drugs - Forbes

Artificial Intelligence is driving the UK’s NextGen jobs – Study International News

In the UK alone, up to a third of jobs will be automated or likely to change as a result of the emergence of AI impacting 10.5 million workers.

These findings come from a new report Harnessing the Power of AI: The Demand for Future Skills from global recruiter Robert Walters and market analysis experts, Vacancy Soft.

Ollie Sexton, Principal at Robert Walters comments:

As businesses become ever more reliant on AI, there is an increasing amount of pressure on the processes of data capture and integration. As a result, we have seen an unprecedented number of roles being created with data skill-set at their core.

Our job force cannot afford to not get to grips with data and digitalisation. Since 2015 the volume of data created worldwide has more than doubled increasing (on average) by 28 percent year-on-year.

Now is the perfect time to start honing UK talent for the next generation of AI-influenced jobs. If you look at the statistics in this report we can see that demand is already rife, what we are at risk of is a shortage of talent and skills.

IT professionals dedicated to data management appear to be the fastest growing area within large or global entities, with volumes increasing ten-fold in three years an increase in vacancies of 160 percent since 2015.

More generally speaking, data roles across the board have increased by 80 percent since 2015 with key areas of growth including data scientists and engineers.

What has been the most interesting to see is the emergence of data scientist as a mainstream profession with job vacancies increasing by a staggering 110 percent year-on-year. The same trend can be seen with data engineers, averaging 86 percent year-on-year job growth.

Job vacancies for data scientists are increasing by a staggering 110 percent annually. Source: Campaign Creators/Unsplash

The rise of cybercrime has resulted in professional services particularly within banking and financial services hiring aggressively for information security professionals since 2016, however since then, volumes have held steady.

Within professional services, vacancies for data analysts (+19.5 percent), data manager (+64.2 percent), data scientist (+28.8 percent), and data engineer (+62 percent) have all increased year-on-year.

Tom Chambers, Manager Advanced Analytics and Engineering at Robert Walters comments:

The uptake of AI across multiple industries is bringing about rapid change, but with that opportunity.

Particularly, we are seeing retail, professional services and technology industries strive to develop digital products and services that are digitally engaging, secure and instantaneous for the customer leading to huge waves of recruitment of professionals who are skilled in implementing, monitoring and gaining the desired output from facial recognition, check-out free retail and computer vision, among other automation technologies.

Similarly, experimental AI is making huge breakthroughs in the healthcare industry, with the power to replace the need for human, expert diagnoses.

What we are seeing from those businesses that are prepared to invest heavily in AI and data analytics, is they are already outperforming their competitors and so demand for talent in this area shows no signs of wavering.

To download a copy of the report click here.

Can Artificial Intelligence make learning fun?

Artificial Intelligence, if used wisely, holds great potential for students, teachers

The rest is here:

Artificial Intelligence is driving the UK's NextGen jobs - Study International News

Fearing a future of artificial intelligence haves and have-nots – The Seattle Times

Each big step of progress in computing from mainframe to personal computer to internet to smartphone has opened opportunities for more people to invent on the digital frontier.

But there is growing concern that trend is being reversed at techs new leading edge, artificial intelligence.

Computer scientists say AI research is becoming increasingly expensive, requiring complex calculations done by giant data centers, leaving fewer people with easy access to the computing firepower necessary to develop the technology behind futuristic products like self-driving cars or digital assistants that can see, talk and reason.

The danger, they say, is that pioneering artificial intelligence research will be a field of haves and have-nots. And the haves will be mainly a few big tech companies like Google, Microsoft, Amazon and Facebook, which each spend billions a year building out their data centers.

In the have-not camp, they warn, will be university labs, which have traditionally been a wellspring of innovations that eventually power new products and services.

The huge computing resources these companies have pose a threat the universities cannot compete, said Craig Knoblock, executive director of the Information Sciences Institute, a research lab at the University of Southern California.

The research scientists warnings come amid rising concern about the power of the big tech companies. Most of the focus has been on the current generation of technology: search, online advertising, social media and e-commerce. But the scientists are worried about a barrier to exploring the technological future when that requires staggering amounts of computing.

The modern data centers of the big tech companies are sprawling and secretive. The buildings are the size of football fields, or larger, housing rack upon rack with hundreds of thousands of computers. The doors are bulletproof. The walls are fireproof. Outsiders are rarely allowed in.

These are the engine rooms of cloud computing. They help deliver a cornucopia of entertainment and information to smartphones and laptops, and they enable millions of developers to write cloud-based software applications.

But artificial intelligence researchers, outside the big tech companies, see a worrying trend in their field. A recent report from the Allen Institute for Artificial Intelligence observed that the volume of calculations needed to be a leader in AI tasks like language understanding, game playing and common-sense reasoning has soared an estimated 300,000 times in the past six years.

All that computing fuel is needed to turbocharge so-called deep-learning software models, whose performance improves with more calculations and more data. Deep learning has been the primary driver of AI breakthroughs in recent years.

When its successful, there is a huge benefit, said Oren Etzioni, chief executive of the Allen Institute, founded in 2014 by Paul Allen, the billionaire co-founder of Microsoft. But the cost of doing research is getting exponentially higher. As a society and an economy, we suffer if there are only a handful of places where you can be on the cutting edge.

The evolution of one artificial intelligence lab, OpenAI, shows the changing economics, as well as the promise of deep-learning AI technology.

Founded in 2015, with backing from Elon Musk, OpenAI began as a nonprofit research lab. Its ambition was to develop technology at the frontier of artificial intelligence and share the benefits with the wider world. It was a vision that suggested the computing tradition of an inspired programmer, working alone on a laptop, coming up with a big idea.

This spring, OpenAI used its technology to defeat the world champion team of human players at a complex video game called Dota 2. Its software learned the game by constant trial and error over months, the equivalent of more than 45,000 years of game play.

The OpenAI scientists have realized they are engaged in an endeavor more like particle physics or weather simulation, fields demanding huge computing resources. Winning at Dota 2, for example, required spending millions of dollars renting access to tens of thousands of computer chips inside the cloud computing data centers run by companies like Google and Microsoft.

This year, OpenAI morphed into a for-profit company to attract financing and, in July, announced that Microsoft was making a $1 billion investment. Most of the money, OpenAI said, would be spent on the computing power it needed to pursue its goals, which still include widely sharing the benefits of AI after paying off investors.

As part of OpenAIs agreement with Microsoft, the software giant will eventually become the labs sole source of computing.

If you dont have enough compute, you cant make a breakthrough, said Ilya Sutskever, chief scientist of OpenAI.

Academics are also raising concerns about the power consumed by advanced AI software. Training a large, deep-learning model can generate the same carbon footprint as the lifetime of five American cars, including gas, three computer scientists at the University of Massachusetts, Amherst, estimated in a recent research paper. (The big tech companies say they buy as much renewable energy as they can, reducing the environmental impact of their data centers.)

Etzioni and his co-authors at the Allen Institute say that perhaps both concerns about power use and the cost of computing could be at least partially addressed by changing how success in AI technology is measured.

The fields single-minded focus on accuracy, they say, skews research along too narrow a path.

Efficiency should also be considered. They suggest that researchers report the computational price tag for achieving a result in a project as well.

Since their Green AI paper was published in July, their message has resonated with many in the research community.

Henry Kautz, a professor of computer science at the University of Rochester, noted that accuracy is really only one dimension we care about in theory and in practice. Others, he said, include how much energy is used, how much data is required and how much skilled human effort is needed for AI technology to work.

A more multidimensional view, Kautz added, could help level the playing field between academic researchers and computer scientists at the big tech companies, if research projects relied less on raw computing firepower.

Big tech companies are pursuing greater efficiency in their data centers and their artificial intelligence software, which they say will make computing power more available to outside developers and academics.

John Platt, a distinguished scientist in Googles artificial intelligence division, points to its recent development of deep-learning models, EfficientNets, which are much smaller and faster than conventional ones. That democratizes use, he said. We want these models to be trainable and accessible by as many people as possible.

The big tech companies have given universities many millions over the years in grants and donations, but some computer scientists say they should do more to close the gap between the AI research haves and have-nots. Today, they say, the relationship that tech giants have to universities is largely as a buyer, hiring away professors, graduate students and even undergraduates.

The companies would be wise to also provide substantial support for academic research including much greater access to their wealth of computing so the competition for ideas and breakthroughs extends beyond corporate walls, said Ed Lazowska, a professor at the University of Washington.

A more supportive relationship, Lazowska argues, would be in their corporate self-interest. Otherwise, he said, Well see a significant dilution of the ability of the academic community to produce the next generation of computer scientists who will power these companies.

At the Allen Institute in Seattle, Etzioni said, the team will pursue techniques to improve the efficiency of artificial intelligence technology. This is a big push for us, he said.

But Etzioni emphasized that what he was calling green AI should be seen as an opportunity for additional ingenuity, not a restraint or a replacement for deep learning, which relies on vast computing power, and which he calls red AI.

Indeed, the Allen Institute has just reached an AI milestone by correctly answering more than 90% of the questions on a standard eighth-grade science test. That feat was achieved with the red AI tools of deep learning.

Read the original:

Fearing a future of artificial intelligence haves and have-nots - The Seattle Times

Zen and the art of artificial intelligence – The Drum

Zen koans (or riddles) are short questions which can be difficult or even impossible to answer. Things along the lines of 'What is the sound of one hand clapping?' or 'Can a submarine swim?'

These questions do not just confuse the recipient, but also force them to think in a different way; to move forward without a precise destination in mind.

This technique can seemingly be applied for creativity in business. Many business and marketing books are written on the importance of trying to reveal the underlying challenge a brand has to solve. It's critically important to know the problem you want to resolve before figuring out what the solution should be.

In the last ten years, there has been a surge in a lot of new business - think Uber and AirBNB for starters. They've become successful by finding a new solution to problems that have emerged within an existing category. So, can AI help us to think in differently? Could AI open our minds using Zen koans and make us think more creatively? As far as I can see, the answer is yes and no... So far, so Zen.

The gradual AI evolution

One of the early successes in AI was a programme called ELIZA, developed by Joseph Weizenbaum in 1966. He was determined to pass the Turing Test; to fool a human that they were talking to a human when in fact they were conversing with a machine. He realised that an easier way to do this - influenced by therapy - was to always ask open questions. So he programmed ELIZA to always respond this way:

Client: Men are all alike.

ELIZA: IN WHAT WAY?

Client: Theyre always bugging us about something or other.

ELIZA: CAN YOU THINK OF A SPECIFIC EXAMPLE?

Client: Well, my boyfriend made me come here.

ELIZA: YOUR BOYFRIEND MADE YOU COME HERE?

Client: He says Im depressed much of the time.

ELIZA: DO YOU THINK YOU ARE DEPRESSED MUCH OF THE TIME?

However, as great as ELIZA was, it didnt take long for Weizenbaum and others to realise the limitations that conversations with the machine offered. There was no real benefit to the questions; and on this front, things havent improved much since.

In this instance, the questions put forward by the AI and its algorithm were too formulaic and therefore deemed useless.

However, scientists then questioned whether AI and machine learning could respond to non-verbal enquiries and answer questions through action rather than by responding to a specific question.

Proof in the pudding

Think of Chess programmes, where Chess Grand Masters and Chess World Champions can be beaten by a machine. The AI system, AlphaGo, has even defeated internationally recognised players in Go - a Chinese game considered to be far more complex than Chess and less likely to be beaten by brute force.

So, how did AlphaGo do it? The software asked questions through the medium of Go. In move 37 of the second game of four against Go World Champion Lee Sedol, AlphaGo placed a black stone on the line five steps in from the edge of the board. Everyone was shocked.

It turns out that in Go, in the early stages of the game, you only play stones on the outer four lines. Playing on the fifth is considered suboptimal and was ridiculed by the commentators at the time. But, you can guess what happened, right? AlphaGos unorthodox move set-up a strategic play that left Sedol open in the latter stages of that same game. AlphaGo won and went on to win the series 4-1, setting a new standard for AI.

AlphaGo questioned the orthodoxy of the game. Up until that point, Go players and culture had found a local maxima - what they believed was the high point of Go based on a set of rules and principles leading to optimum performance.

But AlphaGo discovered that there was a higher level of performance that could be unlocked by what was traditionally considered a bad move. It exploited this and beat Sedol.

Since that moment, this move has changed the course of the game with players now routinely using the fifth line throughout its early stages. So put more succicntly, AI changed the world of Go.

"Humanity has played Go for thousands of years, and yet, as AI has shown us, we have not yet even scratched the surface," said Go champion, Ke Jie. "The union of human and computer players will usher in a new era."

The effect of AI on advertising

So, does AI have the power to ask probing and creative questions, verbal or non-verbal, that can change the state of play within a game, or more importantly for us, for a brand? Well, yes... But, no as well... Still Zen!

AlphaGo did ask an open question, but it was very much within the concrete frame of reference within the game of Go. This is far more rigid than most situations an organisation would find itself in.

So, to be able to compare AI's knowledge bank to the creative process, it has to be able to operate in environments where rules or parameters don't exist to be able to create something truly new.

Psychologist Margaret Boden suggests there are three types of creativity, that context plays an important part.

So, can AI help marketers into the transformational space?

Unfortunately, theres little evidence that they can. Most examples of creative AI focuses on exploratory creativity and doesnt break the rules. Even those on the inside of the AI revolution, like Judea Pearl, computer scientist and philosopher, best known for championing the probabilistic approach to artificial intelligence, thinks that our current techniques are limited.

"Current machine-learning systems operate almost exclusively in a statistical, or model-blind, mode, which is analogous in many ways to fitting functions to a cloud of data points," she said. "Such systems cannot reason about 'What if?' questions and, therefore, cannot serve as the basis for Strong AI."

Obviously, most powerful ideas are rejected at first; so even if we did have an AI capable of producing them, it's unlikely that the operator would understand the value of its output?

AI can ask questions and sometimes, those questions can be useful and surprising, but only if they're based within the constraints of a particular way of thinking. For now, the only place to get truly transformational creativity is from ourselves and our peers; we need to keep asking better questions and prioritise that ahead of creating better answers.

Like any Zen master - who typically answers every question with another question - before thinking of your next problem to solve at work, take a step back, look at your brand and try to come up with a better question first.

As Profsssor Luciano Floridi, puts it: "Data do not speak by themselves, we need smart questioners."

Nick Barthram, founder and strategy partner at Firehaus.

Read more:

Zen and the art of artificial intelligence - The Drum

Patenting Considerations for Artificial Intelligence in Biotech and Synthetic Biology – JD Supra

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at http://www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

As with many websites, JD Supra's website (located at http://www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

We use cookies and other tracking technologies to:

There are different types of cookies and other technologies used our Website, notably:

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

See more here:

Patenting Considerations for Artificial Intelligence in Biotech and Synthetic Biology - JD Supra

New Survey Reveals that HR Leaders Are Prioritizing Artificial Intelligence to Improve the Employee Experience – PRNewswire

SANTA CLARA, Calif., Oct. 1, 2019 /PRNewswire/ --Espressive, the pioneer in artificial intelligence (AI) for enterprise service management and a 2019 Gartner Cool Vendor, today released the findings of a new Pulse Report focused on the top HR service management strategies and initiatives for 2019. The report revealed that increasing the efficiency of HR service management and improving the employee self-help experience will be critical for achieving the top three HR initiatives of 2019: increasing employee retention; improving employee satisfaction; and improving the new-hire onboarding experience. The report, sponsored by Espressive in collaboration with Amazon Web Services (AWS), surveyed senior HR decision makers across a wide variety of industries. With 59 percent of respondents already considering or actively adding virtual employee assistants (i.e., chatbots), it is evident that HR leaders are prioritizing AI to improve the employee experience.

"This past January, Espressive sponsored a similar report on IT service management and found that 62 percent of IT leaders were considering or actively adding virtual support agents," said Pat Calhoun, CEO and founder of Espressive. "The new report, done just six months later, reveals that HR leaders have almost caught up with IT in their desire to leverage AI to improve the employee experience. The new report also revealed that 26 percent would need IT approval even if HR had funding, and another 24 percent said that funding would have to come from IT. With that in mind, organizations would benefit by implementing one solution that can be shared across the enterprise."

Employees are Challenged with Getting Help in the Workplace

Although many enterprises provide an intranet or self-service HR portal for answering questions, survey respondents indicated that only 45 percent of employees commonly search there. More frequently used methods for getting help include calling the help desk (72 percent) and emailing the help desk (64 percent). This is problematic when 34 percent say they have no formal tracking or assignment process and 27 percent use a shared inbox with multiple people potentially working on the same questions.

When asked for employees' biggest complaints about getting answers from HR, the top complaint at 57 percent was that it is too hard to find the right answer when searching the HR portal. Another 53 percent of employees report that they can't keep track of where to go for an answer. 48 percent say that when they reach HR by way of phone or email it takes too long to get a response.

Giving Employees a Personalized Onboarding Experience is a Top Challenge

The report also revealed that new-hire onboarding is top of mind for HR leaders. The top onboarding challenge cited, providing a personalized onboarding experience, ranked 18 percentage points higher than the next challenge. The next three reported onboarding challenges were all related to process: getting hiring managers to kick off the process on time; creating and enforcing a business process framework across departments; and getting new hires to complete onboarding tasks.

"All of the challenges revealed in the new Pulse Report can be solved with automation and AI," said Calhoun. "When employees have one place to go across the enterprise to not only receive answers from HR, but also from IT, Payroll, Workplace Resources, and more, their productivity goes up. And when the self-help experience is similar to what they have come to expect in their consumer lives, employee satisfaction and retention rise as well."

Additional Resources

Pulse Report Methodology

Gatepoint Research fielded this survey during August and September 2019. 44 percent of survey respondents were Fortune 1000 companies and 81 percent were director level and above. The complete Pulse Report on Strategies for HR Service Management is available for download.

About Espressive

Espressive, the pioneer in artificial intelligence (AI) for enterprise service management and a 2019 Gartner Cool Vendor, redefines how employees get help by delivering exceptional employee experiences. Barista, the company's virtual support agent (VSA), brings the ease of consumer virtual assistants, such as Amazon Alexa and Google Home, into the workplace. Barista automates resolution of employee questions, issues, and requests with personalized experiences that result in employee adoption of 80 to 85% and reduced help desk call volume of 40 to 60%. Espressive is backed by General Catalyst Partners and Wing Venture Capital, and is headquartered in Santa Clara, California. Visit http://www.espressive.com for more information.

Media ContactJocelynn StidhamBhava Communications for Espressive703-863-1277 espressive@bhavacom.com

SOURCE Espressive

https://www.espressive.com

See more here:

New Survey Reveals that HR Leaders Are Prioritizing Artificial Intelligence to Improve the Employee Experience - PRNewswire